Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94).
We examined the effects of the synthetic matrix metalloproteinase inhibitor batimastat (BB-94) on lung colonization and spontaneous metastasis of a rat mammary carcinoma, HOSP.1P. This tumor expresses both latent and active forms of the matrix metalloproteinases MMP-2 and MMP-9, although the former, as in human breast cancer, is the most prominent. Administration of batimastat (6 x 30 mg/kg i.p.) inhibited by up to 80% both the number and median weights of HOSP.1P lung colonies following i.v. inoculation of cells. This implies an effect both on seeding efficiency and subsequent tumor development. In spontaneous metastasis assays, limited treatment with batimastat (commencing when s.c. tumors were established and continuing until 5 or 14 days after their surgical removal) significantly inhibited lung metastasis but had little effect on lymphatic metastasis. However, when treatment was initiated 2 days prior to surgery and continued until day 70, 100% of animals survived to day 120 when there was no evidence of metastatic disease. All control animals (n = 25) in two separate experiments died before day 100 with lymphatic, lung, and extrapulmonary metastases. Taken together, these data suggest that lymphatic dissemination by HOSP.1P tumor cells is less susceptible to inhibition by batimastat than vascular invasion, but that long-term treatment can effectively prevent the outgrowth of putative micrometastases in both lymph nodes and lungs, allowing sustained tumor-free survival.
Eccles
S A
SA
Section of Immunology, McElwain Laboratories, Institute of Cancer Research, Surrey, United Kingdom.
Box
G M
GM
Court
W J
WJ
Bone
E A
EA
Thomas
W
W
Brown
P D
PD
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004354:Drug Screening Assays, Antitumor; D005260:Female; D018093:Gelatinases / Q000032:analysis; D008175:Lung Neoplasms / Q000517:prevention & control* / Q000556:secondary; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D020778:Matrix Metalloproteinase 2; D008666:Metalloendopeptidases / Q000032:analysis / Q000037:antagonists & inhibitors*; D009362:Neoplasm Metastasis; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D051381:Rats; D013047:Specific Pathogen-Free Organisms; D015996:Survival Rate; D013876:Thiophenes / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D013876:Thiophenes; D010649:Phenylalanine; C080985:batimastat; D018093:Gelatinases; D008666:Metalloendopeptidases; D020778:Matrix Metalloproteinase 2